Rosuvastatin, in randomized controlled trial, has been shown to reduce the levels of interleukin (IL)-6 and high-sensitivity cardiac troponin I (hs-cTnI) in 50 newly diagnosed HER2-positive breast cancer patients and chemotherapy-treated patients [22,23]. Here, IL6 is linked to breast cancer.